Clinical trials: Resistant Depression, Treatment
Suicidal Ideation
Ketamine For Suicidal Ideation
This study will examine the effects of Intravenous (IV) ketamine both in an outpatient population and with subjects on the inpatient unit with suicidal ideation (SI).
- Trial name
- NCT01507181
- Testing
- Ketamine, Midazolam
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- James Murrough
Treatment Resistant Depression, Inflammation
Specialized Pro-resolving Lipid Mediators and Treatment Resistant Depression
The goal of this clinical trial is to determine the impact of omega-3 fatty acids on the production of anti-inflammatory effects and clinical improvement in people with depression who have not responded well to standard…
- Conditions
- Treatment Resistant Depression, Inflammation, Overweight
- Trial name
- NCT05774665
- Testing
- Omega 3
- Where
- 3 sites in United States
- Volunteers
- 14 people
- Sponsor
- Massachusetts General Hospital
Major Depressive Disorder
Dopaminergic Effects of Adjunctive Aripiprazole on the Brain in Treatment-Resistant Depression
Aripiprazole has been approved by the FDA for augmenting ineffective/partially effective oral antidepressant therapy in patients suffering from major depression. The mechanism by which this augmentation is achieved is not known.
- Trial name
- NCT00953745
- Testing
- Escitalopram, Aripiprazole
- Where
- United States
- Volunteers
- 43 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Major Depressive Episode
The RAFT ECT Study
Severe depression is devastating for those affected and is often associated with significant risk of suicide. Electroconvulsive therapy (ECT) is a highly effective acute treatment for severe depression, but its use and…
- Trial name
- RAFT-ECT (NCT05402657)
- Testing
- Frontoparietal Ultrabrief Right Unilateral (UBRUL-FP) electroconvulsive therapy, Temporoparietal Ultrabrief Right Unilateral (UBRUL-TP) electroconvulsive therapy
- Where
- 7 sites in United States, Australia
- Volunteers
- 156 people
- Sponsor
- The George Institute
Major Depressive Disorder, Depression
Using Neuroimaging to Investigate Major Depressive Disorder
The purpose of this neuroimaging study is to investigate the brain correlates of Major Depressive Disorder with anxiety symptoms as well as potentially identify predictors of treatment outcome.
- Conditions
- Major Depressive Disorder, Depression, Anxiety
- Trial name
- NCT00781677
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- University of Texas Southwestern Medical Center
Major Depressive Disorder
Comparative Effectiveness Clinical Trial of MST Compared to ECT in Major Depressive Disorder
This study was a prospective, open-label comparative effectiveness clinical trial, comparing magnetic seizure therapy (MST) to ECT in patients with Major Depressive Disorder (MDD).
- Trial name
- NCT04216095
- Testing
- Electroconvulsive Therapy (n=30), Magnetic Seizure Therapy (n=30)
- Volunteers
- 60 people
- Sponsor
- Tanta University
Treatment Resistant Depressive Disorder
A Study to Evaluate the Safety and Efficacy of Intranasal Esketamine in Treatment-resistant Depression
The purpose of this study is to assess the efficacy and dose response of intranasal esketamine (Panel A: 28 mg, 56 mg, and 84 mg and Panel B: 14 mg and 56 mg) compared with placebo in improving depressive symptoms in participants…
- Trial name
- SYNAPSE (NCT01998958)
- Testing
- Esketamine 14 mg, Esketamine 28 mg, Esketamine 56 mg
- Where
- 25 sites in United States, Belgium and 1 more
- Volunteers
- 108 people
- Sponsor
- Janssen Research & Development, LLC
Group Meetings
Feasibility of Therapy Integrating Peer-sharing, Technology, Aerobic and Resistance Training (TIPSTART)
The purpose of this randomized controlled clinical trial with first-generation college students with symptoms of mental illness is to test the preliminary feasibility and efficacy of TIPSTART, a multi-faceted, mental health and…
- Trial name
- TIPSTART (NCT04813198)
- Testing
- TIPSTART
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- University of Illinois at Urbana-Champaign
MDD, Treatment Resistant Depression
Three Dosing Regimens of Dextromethorphan (DXM) Reportedly Used in Major Depressive Disorder
This is an open-label dosing pilot study of 15 patients aged 18-50 years of age with diagnoses of Major Depressive Disorder (MDD) randomized to 1 of 3 treatment arms.
- Conditions
- MDD, Treatment Resistant Depression, Smoking Cessation, Smoking
- Trial name
- NCT04226352
- Testing
- Dextromethorphan
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Johns Hopkins University
Resistant Major Depression
Study of Transcranial Direct Current Stimulation (tDCS) as add-on Treatment for Resistant Major Depression
The purpose of the study is to investigate the effect of tDCS applied at the anodic left DLPFC of patients with resistant depression compared to patients treated with conventional therapy.
- Trial name
- DEPRESCO (NCT01428804)
- Testing
- transcranial Direct Current Stimulation (tDCS)
- Where
- France
- Volunteers
- 24 people
- Sponsor
- Centre Hospitalier Universitaire de Besancon
Depression, Treatment Resistant Depression
Investigational TMS Treatment for Depression
This study is aimed to help us learn about the effects of Transcranial Magnetic Stimulation at the forehead versus the left side of the head for treatment of Treatment Resistant Depression.
- Trial name
- NCT03175887
- Testing
- TMS
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- White River Junction Veterans Affairs Medical Center
Bipolar Depression
Efficacy, Safety and Pharmacokinetic Study of Inhaled Esketamine in Treatment-resistant Bipolar Depression
The purpose of the study is to determine the efficacy, safety and pharmacokinetics of inhaled Esketamine in participants with treatment-resistant bipolar depression (TRBD).
- Trial name
- NCT03965871
- Testing
- Esketamine DPI - low dose, Esketamine DPI - medium dose, Esketamine DPI - high dose
- Where
- 12 sites in Poland
- Volunteers
- 88 people
- Sponsor
- Celon Pharma SA
Depression
AZD6765 for Treatment Resistant Depression
The purpose of this study is to determine whether treatment with AZD6765 will have an antidepressant effect with patients who have treatment resistant depression.
- Trial name
- NCT00491686
- Testing
- AZD6765
- Where
- 5 sites in United States
- Volunteers
- 34 people
- Sponsor
- AstraZeneca
Refractory Depression, Anxiety Disorders
Focused Ultrasound and Exosomes to Treat Depression, Anxiety, and Dementias
This study is designed to evaluate the safety and efficacy of exosome deployment with concurrent transcranial ultrasound in patients with refractory, treatment resistant depression, anxiety, and neurodegenerative dementia.
- Conditions
- Refractory Depression, Anxiety Disorders, Neurodegenerative Diseases
- Trial name
- NCT04202770
- Testing
- Exosomes
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- Neurological Associates of West Los Angeles
Major Depressive Disorder, Deep Brain Stimulation
The Efficacy and Prediction of Deep Brain Stimulation for Treatment-resistant Depression
Several open-label trials have shown the therapeutic promise of deep brain stimulation (DBS) targeted to striatal and surrounding capsular areas in treatment-resistant depression (TRD).
- Trial name
- NCT04530942
- Testing
- Deep brain stimulation(Active)
- Where
- China
- Volunteers
- 34 people
- Sponsor
- Ruijin Hospital
Treatment Resistant Depression
Safety, Tolerability, PK and Efficacy of Single Doses of NV-5138 in Healthy Volunteers and Subjects With Treatment-Resistant Depression
Randomized, two-part, placebo-controlled study of single ascending doses of NV-5138 in healthy volunteers, and a single dose of NV-5138 in subjects with Treatment-Resistant Depression (TRD)
- Trial name
- NCT03606395
- Testing
- NV-5138
- Where
- 9 sites in United States
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Navitor Pharmaceuticals, Inc.
Resistant Depression, Treatment, Bipolar Depression
Efficacy and Biomarkers of Response of TBS in Treatment Resistant Depression
Theta Burst Transcranial Magnetic Stimulation (TBS) in dorsolateral prefrontal cortex (DLPFC) has shown efficacy and safety as an adjuvant strategy for resistant to treatment depression (RTD) in daily sessions during 4-6 weeks…
- Trial name
- EMTtfNI (NCT04998773)
- Testing
- Theta Burst Transcranial Magnetic Bilateral Stimulation, Theta Burst Transcranial Magnetic Unilateral Stimulation
- Where
- Spain
- Volunteers
- 96 people
- Sponsor
- Instituto de Investigacion Sanitaria La Fe
Treatment Resistant Depression
Rapid Acting Transcranial Magnetic Stimulation
This study evaluates an accelerated schedule of theta-burst stimulation using a transcranial magnetic stimulation device for treatment-resistant depression.
- Trial name
- NCT04739969
- Testing
- Active TBS-DLPFC
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Stanford University
Behavioral Symptoms, Suicide
Natural History of Depression, Bipolar Disorder and Suicide Risk
Mood disorders, such as depression and bipolar disorder, are difficult to treat. One reason is that there are no objective ways to measure how these disorders affect the body and respond to different treatments.
- Conditions
- Behavioral Symptoms, Suicide, Self-Injurious Behavior, Sensory System Agents
- Trial name
- NCT06462196
- Where
- United States
- Volunteers
- 500 people
- Sponsor
- National Institute of Mental Health (NIMH)
Major Depression
Conventional Bilateral rTMS vs. Bilateral Theta Burst Stimulation for Late-Life Depression
This trial will compare conventional sequential bilateral rTMS to a bilateral theta burst stimulation protocol. The right and left dorsolateral prefrontal cortices will be the site of stimulation in both treatment conditions.
- Trial name
- NCT02998580
- Testing
- LFR followed by HFL, cTBS followed by iTBS
- Where
- Canada
- Volunteers
- 163 people
- Sponsor
- Centre for Addiction and Mental Health